Sotera Health stock barely flinched after earnings, slipping 0.3% to about US$18.86, even though the latest quarter landed with far more force than that move suggests. You are looking at a company in a critical healthcare niche that just reported US$321.4m in Q2 revenue and US$0.19 in basic earnings per share, while adjusted earnings power stepped up again.

The real story now sits on a longer clock. Trailing earnings have grown very sharply, margins are much healthier and the stock trades on a P/E of 32.9x compared with richer peers. The question for investors is how long that gap and this profitability edge can last.

Love Sotera Health's higher margins and earnings momentum but unsure how its valuation compares with other profitable stocks in this space? Take a look at our 49 high quality undervalued stocks for a benchmark list that combines earnings strength with balance sheet support.

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs Q2 2025: US$321.4m vs US$294.3m (up 9.2%)
• Net Income, Q2 2026 vs Q2 2025: US$53.6m vs US$8.0m (very large increase, more than 6x)
• Basic EPS, Q2 2026 vs Q2 2025: US$0.19 vs US$0.03 (very large increase, more than 6x)
• Adjusted EBITDA Margin, Q2 2026 vs Q2 2025: 51.6% vs 51.2% (expanded by 0.4 percentage points)

Prefer simple visuals instead of another wall of earnings tables and ratios? Get a clear snapshot of Sotera Health’s valuation picture in our company report for Sotera Health.

Sotera Health bull case gets real operating support

Bulls argue Sotera Health has an essential, contract backed sterilization and lab platform that can steadily compound earnings through pricing power, capacity additions and margin work. Q2 goes a long way toward backing that up. Revenue grew 9.2% with broad contributions from Sterigenics, Nordion and Nelson Labs, while adjusted EBITDA rose faster and margin edged up to 51.6%. That supports the idea of operating leverage rather than just price led growth.

Capacity and mix are also tracking the optimistic script. Sterigenics delivered both pricing and volume/mix gains, Nordion posted higher revenue tied to Cobalt 60 timing, and Nelson Labs margins recovered sequentially to 32.4% after prior pressure. Net leverage is now 3.0x with about US$950m of liquidity, which lines up with the thesis that strong cash generation and refinancing extend the financial runway for further growth projects.

Sotera Health bear worries partly validated by spend

The bear story focuses on modest organic growth, heavy capital spending, legal overhang and insider selling that could cap returns. Q2 does not fully clear those concerns. Growth remains in the mid single digit to high single digit range with management guiding to 5.25% to 6.75% constant currency revenue growth for 2026. That is healthy but not break out.

Capital intensity is very visible. Capex reached US$46m in Q2 and is guided to US$200m to US$225m for 2026, which will weigh on near term free cash flow even if 2027 is expected to ease. Litigation is still active in Georgia and California despite an immaterial New Mexico settlement, so legal risk has not disappeared. The small share price slip after strong numbers also shows that near term sentiment is still digesting earlier insider selling and equity issuance.

Compare Sotera Health's margin story and capital expenditure heavy growth path with what institutions are expecting. See the consensus price target analysis for Sotera Health to check how closely Wall Street targets line up with the current share price.

Take Control Of Your Next Move

If Sotera Health's mix of higher margins, heavy reinvestment and legal overhang has you watching for a better risk reward balance, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and wait for your preferred entry point. Once you are invested, use the Portfolio Command Center to cut through noise and focus on the key updates that matter to your holdings. For longer term context, tap into the Community to see how other investors are thinking about stories like Sotera Health over time. This way you can spot potential catalysts or risks earlier and stay a step ahead of the market.

Seeking Alternatives Beyond Sotera Health?

Fresh stock ideas move fast and early momentum can pass before the crowd even notices. Scan these curated lists while the data is still sharp and act now.

• Chase durable cash generators that still look overlooked by the market using a curated set of list of solid balance sheet and fundamentals stocks (49 results) before attention floods into the same small group of stocks.
• Ride the build out of next generation AI infrastructure by scanning hand picked 55 AI infrastructure stocks that could benefit if spending momentum holds and valuations have not yet caught up.
• Target income ideas that aim to keep portfolios paying through different market moods using carefully filtered 8 dividend fortresses that focus on yield strength and balance sheet support.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.